← Leaderboards
Jose R Conejo-Garcia
H. Lee Moffitt Cancer Ctr & Res Inst
$21,497,732
Attributed
$23,211,816
Total exposure
17
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,211,816 · 17
By mechanism
R01$16,075,275 · 6
U01$4,125,091 · 1
U54$1,088,281 · 1
R21$812,714 · 2
P20$687,305 · 4
P30$423,150 · 3
Top collaborators
- Javier Pinilla5 shared
- Lubomir Sokol5 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Javier Pinilla$1,917,273
- Lubomir Sokol$857,042
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsCellsBaseT-LymphocyteMalignant Neoplasm Of OvaryOvarian CarcinomaTumor ImmunityMediatingSignal TransductionImmuneDesignImmunotherapyResponseDendritic CellsLeukocytesIn VivoMalignant - DescriptorEffectivenessCytokineLocationPhenotypeRecruitment ActivityNeoplastic Cell
Grant awards (73)
Novel immunotherapies using optimized tumor cell-penetrating antibodies$602,881
R01 · FY2025 · CA · contact PI
Inter-metastatic divergency in small cell lung cancer; implications for the design of future immunotherapies$386,376
R01 · FY2025 · CA · contact PI
Crosstalk between butyrophilins and gamma delta T cells in human cancer$362,250
R01 · FY2025 · CA · contact PI
Immuno-Oncology$47,591
P30 · FY2025 · CA · contact PI
Inter-metastatic divergency in small cell lung cancer; implications for the design of future immunotherapies$367,057
R01 · FY2024 · CA · contact PI
Crosstalk between butyrophilins and gamma delta T cells in human cancer$362,250
R01 · FY2024 · CA · contact PI
OR2H1 is an effective target for CAR T cells in human epithelial tumors$213,852
R21 · FY2024 · CA · contact PI
Immuno-Oncology$47,589
P30 · FY2024 · CA · contact PI
Inter-metastatic divergency in small cell lung cancer; implications for the design of future immunotherapies$401,624
R01 · FY2023 · CA · contact PI
Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma$387,981
R01 · FY2023 · CA · contact PI
OR2H1 is an effective target for CAR T cells in human epithelial tumors$195,472
R21 · FY2023 · CA · contact PI
Immuno-Oncology$47,588
P30 · FY2023 · CA · contact PI
Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma$537,558
R01 · FY2022 · CA · contact PI
B cell-dependent anti-tumor immunity in ovarian cancer$384,851
U01 · FY2022 · CA · contact PI
B cell-dependent anti-tumor immunity in ovarian cancer$376,127
U01 · FY2022 · CA · contact PI
Regulatory Dendritic Cells in Cancer$360,297
R01 · FY2022 · CA · contact PI
Immuno-Oncology$162,194
P30 · FY2022 · CA · contact PI
B cell-dependent anti-tumor immunity in ovarian cancer$781,585
U01 · FY2021 · CA · contact PI
Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma$548,529
R01 · FY2021 · CA · contact PI
Regulatory Dendritic Cells in Cancer$367,650
R01 · FY2021 · CA · contact PI
Rapid Exoproteome Antigen Profiling of antibodies produced in the ovarian cancer microenvironment$250,000
U01 · FY2021 · CA · contact PI
Immunology$56,844
P30 · FY2021 · CA · contact PI
B cell-dependent anti-tumor immunity in ovarian cancer$769,358
U01 · FY2020 · CA · contact PI
Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma$548,529
R01 · FY2020 · CA · contact PI
Initiation and Evolution of the Ovarian Cancer Microenvironment$408,500
R01 · FY2020 · CA · contact PI
Regulatory Dendritic Cells in Cancer$367,650
R01 · FY2020 · CA · contact PI
Immunology$56,848
P30 · FY2020 · CA · contact PI
Immunology$4,496
P30 · FY2020 · CA · contact PI
B cell-dependent anti-tumor immunity in ovarian cancer$781,585
U01 · FY2019 · CA · contact PI
Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma$548,529
R01 · FY2019 · CA · contact PI
Initiation and Evolution of the Ovarian Cancer Microenvironment$396,245
R01 · FY2019 · CA · contact PI
Regulatory Dendritic Cells in Cancer$356,620
R01 · FY2019 · CA · contact PI
B cell-dependent anti-tumor immunity in ovarian cancer$781,585
U01 · FY2018 · CA · contact PI
Initiation and Evolution of the Ovarian Cancer Microenvironment$408,500
R01 · FY2018 · CA · contact PI
Regulatory Dendritic Cells in Cancer$367,650
R01 · FY2018 · CA · contact PI
Initiation and Evolution of the Ovarian Cancer Microenvironment$372,820
R01 · FY2017 · CA · contact PI
Effects of Common Polymorphisms in Immune Sensors in Tumor Immunosurveillance$356,900
R01 · FY2017 · CA · contact PI
Initiation and Evolution of the Ovarian Cancer Microenvironment$341,420
R01 · FY2016 · CA · contact PI
Effects of Common Polymorphisms in Immune Sensors in Tumor Immunosurveillance$309,800
R01 · FY2016 · CA · contact PI
Vascular Leukocytes Influence the Tumor Microenvironment$260,408
R01 · FY2016 · CA · contact PI
Initiation and Evolution of the Ovarian cancer Microenvironment$109,830
R01 · FY2016 · CA · contact PI
Vascular Leukocytes Influence the Tumor Microenvironment$89,762
R01 · FY2016 · CA · contact PI
Effects of common polymorphisms in immune sensors in tumor immunosurveillance$77,366
R01 · FY2016 · CA · contact PI
Initiation and evolution of the ovarian cancer microenvironment$379,960
R01 · FY2015 · CA · contact PI
Effects of common polymorphisms in immune sensors in tumor immunosurveillance$377,972
R01 · FY2015 · CA · contact PI
Vascular Leukocytes Influence the Tumor Microenvironment$340,955
R01 · FY2015 · CA · contact PI
Initiation and evolution of the ovarian cancer microenvironment$370,480
R01 · FY2014 · CA · contact PI
Effects of common polymorphisms in immune sensors in tumor immunosurveillance$366,633
R01 · FY2014 · CA · contact PI
Vascular Leukocytes Influence the Tumor Microenvironment$330,726
R01 · FY2014 · CA · contact PI
Magnetic nanoparticle Immunotherapy against Ovarian Cancer$289,058
U54 · FY2014 · CA · contact PI
Effects of common polymorphisms in immune sensors in tumor immunosurveillance$392,191
R01 · FY2013 · CA · contact PI
Initiation and evolution of the ovarian cancer microenvironment$333,701
R01 · FY2013 · CA · contact PI
Vascular Leukocytes Influence the Tumor Microenvironment$297,976
R01 · FY2013 · CA · contact PI
Initiation and evolution of the ovarian cancer microenvironment$353,435
R01 · FY2012 · CA · contact PI
Vascular Leukocytes Influence the Tumor Microenvironment$318,839
R01 · FY2012 · CA · contact PI
Magnetic nanoparticle Immunotherapy against Ovarian Cancer$318,011
U54 · FY2012 · CA · contact PI
Initiation and evolution of the ovarian cancer microenvironment$363,981
R01 · FY2011 · CA · contact PI
Vascular Leukocytes influence the tumor microenvironment$312,204
R01 · FY2011 · CA · contact PI
Magnetic nanoparticle Immunotherapy against Ovarian Cancer$236,995
U54 · FY2011 · CA · contact PI
Magnetic nanoparticle Immunotherapy against Ovarian Cancer$244,217
U54 · FY2010 · CA · contact PI
Vascular Leukocytes influence the tumor microenvironment$238,127
R01 · FY2010 · CA · contact PI
Boosting anti-tumor immune responses by modulating genes with nanoparticles$223,608
R21 · FY2010 · CA · contact PI
Vascular Leukocytes influence the tumor microenvironment$65,683
R01 · FY2010 · CA · contact PI
Vascular Leukocytes influence the tumor microenvironment$303,810
R01 · FY2009 · CA · contact PI
Boosting anti-tumor immune responses by modulating genes with nanoparticles$179,782
R21 · FY2009 · CA · contact PI
Vascular Leukocytes influence the tumor microenvironment$160,609
R01 · FY2009 · CA · contact PI
Vascular Leukocytes influence the tumor microenvironment$155,391
R01 · FY2009 · CA · contact PI
VASCULAR LEUKOCYTES: BASIC IMMUNOBIOLOGY AND FUNCTIONAL PLASTICITY$39,964
P20 · FY2009 · RR · contact PI
Vascular Leukocytes influence the tumor microenvironment$303,810
R01 · FY2008 · CA · contact PI
VASCULAR LEUKOCYTES: BASIC IMMUNOBIOLOGY AND FUNCTIONAL PLASTICITY$235,061
P20 · FY2008 · RR · contact PI
Vascular Leukocytes influence the tumor microenvironment$303,810
R01 · FY2007 · CA · contact PI
VASCULAR LEUKOCYTES: BASIC IMMUNOBIOLOGY AND FUNCTIONAL PLASTICITY$232,892
P20 · FY2007 · RR · contact PI
COBRE: DMS: VASCULAR LEUKOCYTES AS NOVEL ANTI-TUMOR THERAPEUTIC TARGETS$179,388
P20 · FY2006 · RR · contact PI